After closing a funding round of €4.25 million, ARTHEx confirms the professionalization of its team with the appointment of Nicholas Johnson, M.D., M.Sci., FAAN, as the Chief Medical Advisor of the company. Dr. Johnson is a physician specialist in DM1, associate professor of Neurology and Human and Molecular Genetics, vice chair of research in Neurology at Virginia Commonwealth University and co-principal investigator of the Myotonic Dystrophy Clinical Research Network.
The co-founder and CEO of the company, Dr. Beatriz Llamusí welcomes Dr. Johnson and emphasizes his experience to consolidate the ARTHEx’s project. “Dr. Johnson is a KoL in DM1 with a strong experience on therapeutic trials in DM1 and many other inherited nerve and muscle disorders. Undoubtedly, he will play a crucial role in the design and execution of the clinical development of our therapy.”
“I am excited to assist ARTHEx in the development of novel, precision-based therapies for DM1. They have assembled a dedicated team focused on treating DM1, and have a therapy with a unique mechanism of action. I hope that we can bring this forward for our patients.” said Nicholas Johnson, M.D., M.Sci., FAAN.